Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Semma Therapeutics closes $114m round to advance cell therapy for Type I diabetes

November 30, 2017 By Sarah Faulkner

Semma TherapeuticsSemma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes.

The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative medicine therapies.

Eight Roads Ventures and Cowen Healthcare Investments co-led the round. Existing investors and partners also participated, including Novartis (NYSE:NVS), Medtronic (NYSE:MDT) and the JDRF T1D Fund.

“We are now well positioned, between Semma’s scientific progress and this recent financing, to bring Semma’s lead therapeutic through clinical proof of concept in patients with Type 1 diabetes, while we expand into related arenas and build a leading regenerative medicine company,” chairman Dr. Mark Fishman said in prepared remarks. “We’re delighted that this accomplished group of investors share our mission to cure insulin-dependent diabetes.”

Semma Therapeutics has shown in preclinical studies that its stem cell-derived beta cells perform comparatively to beta cells within human islets as a way to control diabetes both in vitro and in vivo.

“I’m very pleased and impressed to see how far the science has progressed at Semma; what the team has accomplished from a development perspective on both the biology side and engineering side is remarkable,” founder & board observer Douglas Melton added.

“Semma’s scientists have very effectively dedicated themselves to systems that reliably generate cells indistinguishable from human pancreatic beta cells and to the invention of novel devices that are immunologically protective and surgically practical. We’re very encouraged and excited about the potential this program has for diabetic patients and their families.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Funding Roundup, Stem Cells Tagged With: Juvenile Diabetes Research Foundation (JDRF), Medtronic, Novartis, Semma Therapeutics

IN CASE YOU MISSED IT

  • W.L. Gore officials think they can spur insulin delivery system innovation
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • J&J’s Ethicon launches Vistaseal fibrin sealant
  • Senseonics launches Eversense CGM System with non-adjunctive claim
  • ‘Hubble Space Telescope’ for genomics could yield new drugs, materials
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS